Urologic-nephrological Care of Chronic Kidney Disease in Saxony-Anhalt/Magdeburg.

NCT ID: NCT02229435

Last Updated: 2014-09-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1031336 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-12-31

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Statement:

Patients with Chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) under 60 ml/min using the MDRD-6 (Modification of Diet in Renal Disease) formula and/or CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula should undergo nephrological and urological care (diagnosis and treatment) to prevent chronic kidney failure. This is recommended by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI), Kidney Disease Improving Global Outcomes (KDIGO) and European Urological Association (EAU). Renal and postrenal diseases can cause or worsen CKD. Internistic and intrarenal diseases can caused or worsen CKD. All diseases affecting CKD should be treated and the medical care should be optimized.

Hypothesis:

Not all patients with CKD receive urological and nephrological care. Interdisciplinary work of outpatient working urologists and nephrologists in the metropolitan area Magdeburg / Saxony-Anhalt Germany is unknown. An descriptive analysis of interdisciplinary treatment connection of CKD patients for an orientating statement is needed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Medical Laboratory Schenk-Ansorge Magdeburg Saxony-Anhalt Germany receives all blood samples of outpatient patients of the medical practices of the metropolitan area Magdeburg Saxony-Anhalt Germany. Every patient has a lifetime identification number Independent of the submitting practice. Every submitting medical doctor has a lifetime identification number and is identified by her/his medical subject /specialization. This analysis is based on that laboratory database. For that study a cohort of 1.031.336 patients from 12/2004 to 08/2014 is evaluated, that had been received blood tests with measurement of serum creatinine. For every serum creatinine an eGGR is calculated with the guideline recommended formula.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease (CKD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

eGFR <60ml/min

Patients with CKD with eGFR \<60 ml/min (CKD-EPI or MDRD) 12/2004-08/2014 of Medical Laboratory, Prof. Schenk / Dr. Ansorge and Colleagues, GbR, Am Neustädter Feld 47, 39124 Magdeburg, Germany.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Measured serum creatinine and estimated glomerular filtration rate
* eGFR \< 60 ml/min

Exclusion Criteria

* dialysis
* no serum creatinine measured
* Age \< 18 years
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical Laboratory Schenk-Ansorge Magdeburg Germany.

UNKNOWN

Sponsor Role collaborator

University of Magdeburg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Johann J. Wendler, MD

Dr. med.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Johann J Wendler, Dr.

Role: PRINCIPAL_INVESTIGATOR

Urology University Magdeburg

Martin Schostak, Prof. Dr.

Role: STUDY_CHAIR

Urology University Magdeburg

Herwart Schenk, Prof. Dr.

Role: STUDY_DIRECTOR

Medical Laboratory Am Neustädter Feld 47, 39124 Magdeburg, Saxony-Anhalt, Germany.

Constanze Tienken, Cand. med.

Role: PRINCIPAL_INVESTIGATOR

Doctorand Urology University Magdeburg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Urology University Magdeburg

Magdeburg, Saxony-Anhalt, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Related Links

Access external resources that provide additional context or updates about the study.

http://www.schenk-ansorge.de/Kontakt.aspx

Medical Laboratory Schenk-Ansorge Magdeburg, Germany.

http://urologie.uni-magdeburg.de/urologie.html

Department of Urology University Magdeburg, Germany.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

URO-MD-040

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

SOP's for CKD-MBD-Biomarkers
NCT02708368 COMPLETED
Determination of Kidney Function
NCT00001978 TERMINATED